Login to Your Account



In 'Sly' phase III move, Ultragenyx looks to filings for rhGUS in MPS 7

By Marie Powers
News Editor

Friday, July 15, 2016

Ultragenyx Pharmaceutical Inc. enrolled only 12 patients in the pivotal phase III study of its recombinant human beta-glucuronidase candidate, also known as UX003, to treat ultra-rare MPS 7, or Sly syndrome.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription